Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 11;12(4):849.
doi: 10.3390/biomedicines12040849.

Investigation of the Effect of Therapeutic Plasma Exchange for TAFRO Syndrome: A Pilot Study

Kosuke Sonoda  1 , Masamichi Komatsu  2 , Yoko Ozawa  2 , Hiroshi Yamamoto  2   3 , Yuji Kamijo  1
Affiliations

Investigation of the Effect of Therapeutic Plasma Exchange for TAFRO Syndrome: A Pilot Study

Kosuke Sonoda et al. Biomedicines. .

Abstract

TAFRO syndrome is a rare systemic inflammatory disorder with a fatal course. Nevertheless, a definitive treatment strategy has not yet been established. Anti-inflammatory therapies, including glucocorticoid treatment and immunosuppressants, have not been satisfactory. Therefore, new treatment options are needed for patients with TAFRO syndrome. The effectiveness of therapeutic plasma exchange (TPE) has mainly been reported in several case reports. In this case series study, we investigated the effect of TPE on TAFRO syndrome. We reviewed six consecutive cases with TAFRO syndrome treated at Shinshu University Hospital. All of them underwent TPE. A significant improvement in mean blood pressure, albumin, total bilirubin, and C-reactive protein was observed after TPE. Furthermore, early TPE treatment was suggested to have an impact on the prognosis. More intensive studies are needed to emphasize the overall conclusion obtained that TPE can be an effective/acceptable treatment option for TAFRO syndrome.

Keywords: TAFRO syndrome; therapeutic plasma exchange; thrombotic microangiopathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Changes in clinical data before and after therapeutic plasma exchange. Data have been presented as median values (interquartile range). * p < 0.05.
Figure 2
Figure 2
Changes in clinical data before and after therapeutic plasma exchange on the first session. * p < 0.05.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Takai K., Nikkuni K., Shibuya H., Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki. 2010;51:320–325. - PubMed
    1. Dispenzieri A., Fajgenbaum D.C. Overview of Castleman disease. Blood. 2020;135:1353–1364. doi: 10.1182/blood.2019000931. - DOI - PubMed
    1. Fajgenbaum D.C., Uldrick T.S., Bagg A., Frank D., Wu D., Srkalovic G., Simpson D., Liu A.Y., Menke D., Chandrakasan S., et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129:1646–1657. doi: 10.1182/blood-2016-10-746933. - DOI - PMC - PubMed
    1. Masaki Y., Kawabata H., Takai K., Kojima M., Tsukamoto N., Ishigaki Y., Kurose N., Ide M., Murakami J., Nara K., et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int. J. Hematol. 2016;103:686–692. doi: 10.1007/s12185-016-1979-1. - DOI - PubMed
    1. Masaki Y., Kawabata H., Takai K., Tsukamoto N., Fujimoto S., Ishigaki Y., Kurose N., Miura K., Nakamura S., Aoki S. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int. J. Hematol. 2020;111:155–158. doi: 10.1007/s12185-019-02780-1. - DOI - PubMed